HT
AKRO

Headlands Technologies’s Akero Therapeutics AKRO Stock Holding History

Headlands Technologies’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,647
Closed -$980K – 661
2025
Q3 		$980K Buy
20,647
+12,318
+148% +$596K 0.08% 241
2025
Q2 		$444K Buy
8,329
+8,208
+6,783% +$373K 0.05% 328
2025
Q1 		$4.9K Sell
121
-1,914
-94% -$81.1K ﹤0.01% 1001
2024
Q4 		$56.6K Sell
2,035
-4,631
-69% -$140K 0.01% 792
2024
Q3 		$191K Sell
6,666
-10,337
-61% -$269K 0.02% 537
2024
Q2 		$399K Buy
17,003
+12,786
+303% +$273K 0.04% 321
2024
Q1 		$107K Buy
4,217
+3,024
+253% +$72.6K 0.03% 524
2023
Q4 		$27.9K Buy
+1,193
New +$23.5K 0.01% 620

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Headlands Technologies's AKRO Position: Q4 2025 in Review

Headlands Technologies sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 20,647 shares — an estimated $980K sold.

Headlands Technologies first reported a position in AKRO in Q4 2023 and held it in 8 quarters. The position peaked at $980K in Q3 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Headlands Technologies reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Headlands Technologies sold 20,647 Akero Therapeutics shares in Q4 2025, an estimated $980K.
  • Headlands Technologies first reported a position in Akero Therapeutics in Q4 2023 and held it in 8 quarters.
  • Headlands Technologies's Akero Therapeutics position peaked at $980K in Q3 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Headlands Technologies's 13F filing for Q4 2025, filed 13 Feb 2026.